SAB Biotherapeutics reports FY2023 net loss $42.2M; cash $56.6M; funding into 2026

SAB Biotherapeutics, Inc.

Net loss $42.2M for FY2023 versus $18.7M in 2022; cash and equivalents $56.6M as of Dec 31, 2023.
Completed equity financing up to $110M; expects cash with Tranche B warrant exercise to fund operations into 2026.
Phase 1 trial of SAB-142 for Type 1 diabetes on track for data by end of 2024.
Appointed Michael G. King Jr. as CFO; Andrew Moin and Katie Ellias added to board.
R&D expenses $16.5M (down from $36.4M); G&A $23.8M (up from $16.4M).

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

SAB Biotherapeutics, Inc. reported the year and quarter ended December 31, 2023 results: net income net loss of $42.2 million.

Period: the year and quarter ended December 31, 2023
Net income: net loss of $42.2 million
Result: reported results

Exact text from the filing

SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

View on SEC.gov

Browse all earnings releases →

SAB Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-038429

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.